KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2016 - 2025)

Supernus Pharmaceuticals has reported Income from Continuing Operations over the past 15 years, most recently at 4105000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 126.78% to 4105000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 38584000.0 through Dec 2025, down 152.23% year-over-year, with the annual reading at 38550000.0 for FY2025, 152.19% down from the prior year.
  • Income from Continuing Operations was 4105000.0 for Q4 2025 at Supernus Pharmaceuticals, up from 45117000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 38497000.0 in Q3 2024 and troughed at 45117000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 6759000.0 (2021), against an average of 7534600.0.
  • Year-over-year, Income from Continuing Operations soared 2506.53% in 2024 and then tumbled 8373.43% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 2442000.0 in 2021, then surged by 944.55% to 25508000.0 in 2022, then crashed by 95.39% to 1175000.0 in 2023, then soared by 1204.51% to 15328000.0 in 2024, then tumbled by 126.78% to 4105000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Income from Continuing Operations are 4105000.0 (Q4 2025), 45117000.0 (Q3 2025), and 22469000.0 (Q2 2025).